Cargando…

Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study

OBJECTIVE: Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. METHODS: The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Bijun, Tan, Xiaoming, Lou, Yueyan, Zheng, Yu, Zhang, Liyan, Wu, Xueling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Retrospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591656/ https://www.ncbi.nlm.nih.gov/pubmed/34758674 http://dx.doi.org/10.1177/03000605211046173

Ejemplares similares

Serum S100A12 levels are correlated with clinical severity in patients with dermatomyositis-associated interstitial lung disease
por: Lou, Yueyan, et al.
Publicado: (2019)

The cryobiopsy in interstitial lung diseases guided by probe‐based confocal laser endomicroscopy is feasible
por: Zheng, Yu, et al.
Publicado: (2023)

The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease
por: Lou, Yueyan, et al.
Publicado: (2021)

Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease
por: Lou, Yueyan, et al.
Publicado: (2020)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)

Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
por: Li, Lei, et al.
Publicado: (2022)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma
por: Qi, Can, et al.
Publicado: (2022)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Retracted: The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Establishment of a prognostic model for patients with sepsis based on SOFA: a retrospective cohort study
por: Liu, Hui, et al.
Publicado: (2021)

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
por: Han, Baohui, et al.
Publicado: (2018)

Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
por: Zheng, Hui, et al.
Publicado: (2021)

Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer
por: Liu, Qianfei, et al.
Publicado: (2020)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma
por: De Wilde, Nika, et al.
Publicado: (2022)

Ilizarov bone transport to treat infected nonunion of long bones: a multicenter retrospective cohort study
por: Xie, Jiang, et al.
Publicado: (2021)

Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study
por: Zhang, Ge, et al.
Publicado: (2022)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020)

Case report of severe pneumothorax due to lung cancer treated with anlotinib
por: Lu, Haowei, et al.
Publicado: (2023)

Relationship between hematological parameters and bronchopulmonary dysplasia in premature infants
por: Jiang, Junsheng, et al.
Publicado: (2023)

Bronchial Fistula: Rare Complication of Treatment with Anlotinib
por: DENG, Pengbo, et al.
Publicado: (2020)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs
por: He, Qiong, et al.
Publicado: (2021)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Mortality and associated risk factors in patients with severe methanol or ethylene glycol poisoning treated with dialysis: a retrospective cohort study
por: Kuusela, Emma, et al.
Publicado: (2022)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Frontiers Production Office,
Publicado: (2022)

Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
por: Ye, Xuanting, et al.
Publicado: (2023)

Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study
por: Dai, Yi-Jun, et al.
Publicado: (2023)

A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study of 55 cases
por: Sun, Jie, et al.
Publicado: (2021)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
por: Zheng, Shengnan, et al.
Publicado: (2021)

Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study
por: Scheer, René, et al.
Publicado: (2017)

Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study
por: Sheng, Xin-Yu, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
por: Chen, Ling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tbjc4u84vc02fb126lg437220